CAMBRIDGE, Mass., Sept. 7, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President and Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, September 10, 2012 at 3:35 p.m. (EDT) at the Grand Hyatt in New York, New York. A live webcast of Merrimack's presentation can be accessed by visiting the investor relations section of the company's website at investors.merrimackpharma.com. A replay of the webcast will be archived on Merrimack's website for two weeks following the presentation. About Merrimack Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development. Forward-looking statements Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
CONTACT: Investor & Media Contact: Kathleen Petrozzelli Gallagher Corporate Communications, Merrimack 617-441-1043, email@example.com Media Contact: Betsy Stevenson RaymondStevenson Healthcare Communications 860-984-1424, firstname.lastname@example.org